Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

Results presented on Tuesday at the American Association for Cancer Reserch include data on the combined use of tissue and ...

Mike Fazio, director of value-based care at Navista, Cardinal Health, discusses a trending topic at the 2025 Community ...

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now ...

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout ...

A panelist discusses how viral suppression in HIV patients means achieving undetectable virus levels (below 50 or 20 copies ...

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering ...

As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...